Leerink Partners analyst Marc Goodman has maintained their bullish stance on OCS stock, giving a Buy rating on April 15.
Marc Goodman has given his Buy rating due to a combination of factors that highlight Oculis Holding’s promising future. The company is advancing three innovative programs, including a neuroprotective agent, privosegtor (OCS-05), which shows potential in treating several axonal diseases. Additionally, Oculis is developing a dry eye treatment, licaminlimab, using a novel precision approach, and continues to progress with OCS-01 for diabetic macular edema (DME), with pivotal data expected in the second quarter of 2026.
Oculis recently hosted an R&D event featuring key opinion leaders who reviewed the clinical development plans for these assets. Notably, the company plans to file a New Drug Application for OCS-01 in ocular surgery after the DME filing next year, reallocating resources to advance privosegtor. New data showed that OCS-05 effectively lowered a critical biomarker of neuronal degeneration, garnering positive feedback from experts. Furthermore, Oculis is preparing to initiate trials for privosegtor in Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) and meet with the FDA to discuss several development programs, underscoring its strategic focus on growth and innovation.
In another report released on April 15, Stifel Nicolaus also reiterated a Buy rating on the stock with a $35.00 price target.